top of page


StemoniX CEO Ping Yeh Speaks at the 2020 New Jersey Association for Biomedical Research 3Rs Webinar Series

October 20, 2020 – In his talk, “Making Human Organs and the Path to Replacement,” Mr.  Yeh discusses how the Company’s physiologically-relevant microOrgan® technology and human-first paradigm are de-risking drug discovery and preclinical drug development by compressing the pipeline and  ensuring only the safest and most effective compounds are advanced to the clinic. 

StemoniX Announces Addition to Board of Directors

October 19, 2020 – Mr. Fletcher brings more than 30 years of strategy and financing experience across the Pharmaceutical and Healthcare Industry to the Board

StemoniX 3D Oncology & Tissue Models Conference

September 30 - October 1, 2020 – StemoniX Director of R&D, Dr. Cassiano Carromeu, did a fabulous presention on "Drug Discovery in 3D: Disease Modeling, Hit Stratification, and Clinical Translation with Human iPSC-derived 3D Neurospheroids" on Day 1. Dr. Blake Anson presented our poster, "Finding the Needle in the Haystack," on Day 2.

View our poster
StemoniX participates in SBI2 High Content Meeting

September 16 - 17, 2020 –  StemoniX exhibited and presented at the 7th Annual SBI2 High Content Meeting. Contact us to learn more about our poster: hiPSC-derived neurospheroids support assessment of glioblastoma cancer stem cell behavior and compound responses

View our poster

September 7, 2020 – The StemoniX microBrain 3D platform was featured in a recent BioTechniques article! Read how our partners at Molecular Devices have used the microBrain 3D high-throughput, hiPSC-derived platform to study neurological dysfunction

StemoniX featured in MinneInno!

August 24, 2020 – Stemonix Inc. has agreed to a merger with Cancer Genetics Inc., a publicly traded pharmaceutical company based in Rutherford, N.J.

StemoniX participates in the LabRoots Coronavirus 2020 Virtual Poster Session

July, 2020 – StemoniX presented a poster titled Using hiPSC-derived neural cultures to assess the safety of potential anti-viral therapeutics outlining how our high-content, consistent human cultures can be used to determine the safety and efficacy of anti-viral therapeutics

StemoniX participates in the BIO 2020 Digital International Convention

June 8-12, 2020 – Ping Yeh, StemoniX CEO, joined a panel discussing "Organs-on-a-Chip and AI: Realizing Potential Efficiencies in Drug Discovery and Development."

StemoniX ® CEO, Ping Yeh, Participates in an Organ- on-a-Chip and AI Focused Panel at the BIO2020 Digital Convention

June 9, 2020 – StemoniX ® , Inc., a biotech company revolutionizing how new medicines are discovered, announced today that its CEO and Co-founder, Ping Yeh, has joined a panel of experts from the FDA, the NIH, Pharma, and AI at this year’s BIO2020 Digital conference.

StemoniX featured in the inaugural INNOVATE Minnesota!

May, 2020 – We're thrilled to be part of the inaugural INNOVATE Minnesota book! Learn more about StemoniX. Read our company profile!

bottom of page